AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.
Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates. We look forward to utilising their Discovery Engine to enhance our existing oncology pipeline.”
Under the terms of the agreement, Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from the selected tumours.
Immunome will receive an upfront payment of $30M and will be eligible to receive additional platform access payments in the aggregate amount of up to $70M based on AbbVie’s election for Immunome to continue research using its Discovery Engine.
Immunome is also eligible to receive development and first commercial sale milestones of up to $120M per target with respect to certain products derived from target-antibody pairs that AbbVie elects to purchase, with potential for further sales-based milestones as well as tiered royalties on global sales.
Purnanand Sarma, President and CEO of Immunome, added: “AbbVie shares our vision of harnessing the power of the human immune response to yield novel and first-in-class therapeutics that represent a shift in the cancer discovery paradigm. We are delighted to be working with AbbVie and look forward to leveraging their vast development and commercialisation expertise in bringing new therapies to patients suffering from life-threatening cancers.”